S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.54 (+1.07%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.13 (-1.18%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.09%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.63 (-0.91%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)

Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News

$35.17
-0.59 (-1.65%)
(As of 09/22/2023 ET)
Compare
Today's Range
$35.05
$36.03
50-Day Range
$35.07
$39.73
52-Week Range
$31.79
$43.75
Volume
267,832 shs
Average Volume
368,663 shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.40

Xenon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.09 Rating Score
Upside/​Downside
49.0% Upside
$52.40 Price Target
Short Interest
Bearish
4.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Xenon Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$967,500 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.89) to ($3.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

490th out of 968 stocks

Pharmaceutical Preparations Industry

213th out of 445 stocks


XENE stock logo

About Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

XENE Price History

XENE Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to Sell
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Here's what Wall Street expects from Xenon Pharmaceuticals's earnings
11 Best Healthcare Stocks Under $50
Expert Ratings for Xenon Pharmaceuticals
Guggenheim Sticks to Their Buy Rating for Xenon (XENE)
Stifel Nicolaus Keeps Their Buy Rating on Xenon (XENE)
See More Headlines
Receive XENE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

XENE Company Calendar

Last Earnings
8/09/2023
Today
9/22/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XENE
Employees
203
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$52.40
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+49.0%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
11 Analysts

Profitability

Net Income
$-125,370,000.00
Pretax Margin
-123,568.95%

Debt

Sales & Book Value

Annual Sales
$9.43 million
Book Value
$11.54 per share

Miscellaneous

Free Float
60,663,000
Market Cap
$2.26 billion
Optionable
Optionable
Beta
1.34
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ian C. Mortimer C.M.A. (Age 47)
    CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director
    Comp: $973.76k
  • Ms. Sherry Aulin (Age 40)
    Chief Financial Officer
    Comp: $3.03M
  • Ms. Andrea DiFabio J.D. (Age 55)
    Chief Legal Officer & Corp. Sec.
    Comp: $200.51k
  • Dr. Christopher E. Von Seggern M.B.A. (Age 44)
    M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer
    Comp: $618.07k
  • Dr. Christopher John Kenney M.D.Dr. Christopher John Kenney M.D. (Age 52)
    Chief Medical Officer
    Comp: $684.22k
  • Ms. Shelley McCloskey B.A. (Age 63)
    Exec. VP of HR
  • Dr. Robin P. Sherrington Ph.D. (Age 62)
    Exec. VP of Strategy & Innovation
  • Dr. James R. Empfield Ph.D. (Age 62)
    Exec. VP of Drug Discovery
  • Ms. Sheila M. Grant M.B.A.
    M.Sc., MBA, Exec. VP of R&D Operations













XENE Stock - Frequently Asked Questions

Should I buy or sell Xenon Pharmaceuticals stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares.
View XENE analyst ratings
or view top-rated stocks.

What is Xenon Pharmaceuticals' stock price forecast for 2023?

11 Wall Street analysts have issued twelve-month price objectives for Xenon Pharmaceuticals' shares. Their XENE share price forecasts range from $47.00 to $60.00. On average, they expect the company's stock price to reach $52.40 in the next year. This suggests a possible upside of 49.0% from the stock's current price.
View analysts price targets for XENE
or view top-rated stocks among Wall Street analysts.

How have XENE shares performed in 2023?

Xenon Pharmaceuticals' stock was trading at $39.43 at the beginning of 2023. Since then, XENE stock has decreased by 10.8% and is now trading at $35.17.
View the best growth stocks for 2023 here
.

When is Xenon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our XENE earnings forecast
.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.03. Xenon Pharmaceuticals's revenue was down 100.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.55) EPS.

What ETFs hold Xenon Pharmaceuticals' stock?
What other stocks do shareholders of Xenon Pharmaceuticals own?
What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Driehaus Capital Management LLC (7.42%), Polar Capital Holdings Plc (4.71%), Braidwell LP (2.85%), Perceptive Advisors LLC (1.91%), BlackRock Inc. (1.56%) and Nicholas Investment Partners LP (1.24%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends
.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $35.17.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.26 billion and generates $9.43 million in revenue each year. The biopharmaceutical company earns $-125,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

The company employs 203 workers across the globe.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.

This page (NASDAQ:XENE) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -